Cabaletta Bio (CABA) Accounts Payables (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Accounts Payables of $6.6 million for Q4 2025, up 34.8% year-over-year from $4.9 million in Q4 2024, and down 19.73% quarter-over-quarter from $8.3 million in Q3 2025.
Cabaletta Bio (CABA) Accounts Payables (2018 - 2026) Analysis & Trends
Cabaletta Bio's Accounts Payables history runs 8 years deep, the most recent figure standing at $6.6 million for Q4 2025.
- In Q4 2025, Accounts Payables rose 34.8% year-over-year to $6.6 million; the TTM figure through Dec 2025 stood at $6.6 million (up 34.8% YoY), while the FY2025 annual figure was $6.6 million, up 34.8% from the prior year.
- Accounts Payables for Q4 2025 stood at $6.6 million, down from $8.3 million in the prior quarter.
- The five-year high for Accounts Payables was $8.3 million in Q3 2025, with the low at $1.3 million in Q1 2021.
- The 5-year median for Accounts Payables is $3.8 million (2022), against an average of $3.9 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables slumped 39.78% in 2024, then surged 279.22% in 2025.
- Cabaletta Bio's Accounts Payables stood at $2.3 million in 2021, then increased by 5.57% to $2.5 million in 2022, then jumped by 84.61% to $4.5 million in 2023, then advanced by 8.27% to $4.9 million in 2024, then jumped by 34.8% to $6.6 million in 2025.
- Business Quant data shows CABA's Accounts Payables at $6.6 million in Q4 2025, $8.3 million in Q3 2025, and $7.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 5.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.81 Mn |
| Dec 31, 2025 | 6.64 Mn |
| Sep 30, 2025 | 8.27 Mn |
| Jun 30, 2025 | 7.19 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 4.22 Mn |
| Mar 31, 2024 | 5.84 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | 3.62 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Mar 31, 2023 | 3.96 Mn |
| Dec 31, 2022 | 2.46 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 2.45 Mn |
| Mar 31, 2022 | 3.91 Mn |
| Dec 31, 2021 | 2.33 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 2.37 Mn |